Bayer’s St. Louis legacy: 10 years of litigation

en years after Bayer's landmark $63 billion acquisition of St. Louis-based Monsanto, the German pharmaceutical giant is finally seeing the legal tide turn — but the battle is far from over. In this episode, St. Louis Business Journal reporter Jim Drew joins host Erik to break down a recent flurry of major developments in Bayer's long-running Roundup litigation.The U.S. Supreme Court handed Bayer a decisive 7-2 victory, ruling that federal pesticide law preempts state-level "failure to warn" lawsuits — potentially clearing a path to dismiss tens of thousands of claims. At the same time, a St. Louis Circuit Court is weighing a proposed $7.25 billion class action settlement that would resolve 67,000 Roundup cases, even as a faction of cancer victims pushes back on the terms.We also look at Bayer's surprising move to create a separate business unit — Ruvian — to house its Roundup operations, raising questions about liability management and whether a full spinoff could be on the horizon. And as insurers fight back against Bayer's attempts to recoup billions in legal costs, we examine what the science still doesn't know about glyphosate — and why this story may be far from its final chapter.Cancer research continues as Supreme Court sides with Bayer on Roundup labelsJust a mBayer says Supreme Court ruling should dismiss 'vast majority' of Roundup lawsuitsoment...Judge delays Bayer's $7.25B Roundup settlement hearing amid objectionsJudge declares mistrial in Roundup lawsuit after US Supreme Court rulingBayer creates new unit for Roundup business, based in Creve CoeurInsurers attack Bayer bid for coverage (Round Up)